Atossa Therapeutics (ATOS) Change in Cash (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Change in Cash of -$9.6 million for Q1 2026, down 60.54% year-over-year from -$24.3 million in Q1 2025, and up 9.15% quarter-over-quarter from -$10.5 million in Q4 2025.
Atossa Therapeutics (ATOS) Change in Cash (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Change in Cash for 16 consecutive years, with -$9.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash fell 60.54% year-over-year to -$9.6 million; the TTM figure through Mar 2026 stood at -$33.4 million (down 77.23% YoY), while the FY2025 annual figure was -$29.8 million, down 71.41% from the prior year.
- Change in Cash improved to -$9.6 million in Q1 2026 per ATOS's latest filing, from -$10.5 million in the prior quarter.
- Across five years, Change in Cash topped out at -$3.7 million in Q4 2024 and bottomed at -$10.5 million in Q4 2025.
- Historically, Change in Cash has averaged -$6.2 million across 5 years, with a median of -$5.9 million in 2022.
- Annual changes were most pronounced in 2022 — Change in Cash tumbled 241.56% — and 2024, when it soared 35.92%.
- Atossa Therapeutics' Change in Cash stood at -$6.5 million in 2022, then grew by 13.99% to -$5.6 million in 2023, then surged by 33.91% to -$3.7 million in 2024, then slumped by 186.42% to -$10.5 million in 2025, then increased by 9.15% to -$9.6 million in 2026.
- Business Quant data shows ATOS's Change in Cash at -$9.6 million in Q1 2026, -$10.5 million in Q4 2025, and -$6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | -5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.62 Mn |
| Mar 31, 2026 | -9.58 Mn |
| Dec 31, 2025 | -10.55 Mn |
| Sep 30, 2025 | -6.01 Mn |
| Jun 30, 2025 | -7.26 Mn |
| Mar 31, 2025 | -5.97 Mn |
| Dec 31, 2024 | -3.68 Mn |
| Sep 30, 2024 | -4.76 Mn |
| Jun 30, 2024 | -4.43 Mn |
| Mar 31, 2024 | -4.50 Mn |
| Dec 31, 2023 | -5.57 Mn |
| Sep 30, 2023 | -5.36 Mn |
| Jun 30, 2023 | -4.48 Mn |
| Mar 31, 2023 | -7.02 Mn |
| Dec 31, 2022 | -6.48 Mn |
| Sep 30, 2022 | -8.17 Mn |
| Jun 30, 2022 | -5.95 Mn |
| Mar 31, 2022 | -4.89 Mn |
| Dec 31, 2021 | -3.66 Mn |
| Sep 30, 2021 | -2.39 Mn |